HDAC inhibitors like vorinostat have shown promising outcomes by augmenting cell death and supressing advanced pancreatic (and other) cancers [47, 49, 50, 53], and our data now implicate S100PBP in the mechanisms of their actions. This evidence concerns the gene HDAC9 and cancer.